

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Available online at www.sciencedirect.com

Journal of Hospital Infection

journal homepage: www.elsevier.com/locate/jhin



Multi-drug-resistant infections in the COVID-19 era: a framework for considering the potential impact

Sir,

The recent report by Jolivet *et al.* highlights the progress being made on multi-drug-resistant (MDR) infections [1]. However, this report predates the coronavirus disease 2019 (COVID-19) pandemic and it is unclear what the impact will be on MDR infections globally. There are reports of high use of broad-spectrum antibiotics in the hospital setting, recognized as a risk factor for hospital-acquired infections (HAIs) with MDR organisms [2–4]. Recent data have also highlighted significant rates of hospital-acquired pneumonia [2]. High rates of admission, shortages of staff and personal protective

equipment (PPE), and high-acuity patients with prolonged stays in overcrowded facilities may also affect the rates of HAI with MDR pathogens [2,3]. Moreover, severe COVID-19, which particularly affects elderly patients with multiple comorbidities, may be an important factor in determining changes in colonization pressure [2–4]. Equally, wider recognition of the importance of HAIs, with stricter hygiene policies, high use of PPE, and patients being cared for in new temporary hospitals, could all mitigate against this threat [2,3]. Table I summarizes the potential relative impact of these various factors to provide a conceptual framework for determining the overall impact [2–6].

Novel cost-effective surveillance programmes of MDR HAIs in both high- and low/middle-income countries will be even more important in the post-COVID-19 era, combined with enhanced stewardship interventions. These need to be planned for now, to facilitate future integration with any future pandemic surveillance.

Conflict of interest statement None declared.

Table I

Potential impact of coronavirus disease 2019 (COVID-19) on hospital transmission of multi-drug-resistant organisms (MDROs)

	Factors that may favour MDRO transmission	Factors that may prevent MDRO transmission
Infection prevention and control practices and use of PPE	Shortage of PPE due to the rapid increase in people admitted with COVID-19 [3—5]	Isolation of patients with COVID-19, application of enhanced standard precautions (hand hygiene policy and respiratory hygiene), use of PPE (when available) and appropriate environmental disinfection procedures [3–5]
Hospital overcrowding	The need for large-scale medical assistance exceeds the availability of hospital beds, resulting in overcrowded facilities [3,6]	Lack of beds in ICUs has led to new facilities being developed both within and outside current hospital ICU settings, many with existing colonization with MDROs [3,5]
HCWs	High rates of staff sickness and nosocomial acquisition of COVID-19, leading to low HCW:patient ratios [3,5,6]	COVID-19-designed ICUs with dedicated HCWs may have decreased cross-transmission of nosocomial infections [3,4]
Demographic features of patients affected by COVID-19	Elderly patients with comorbidities require prolonged hospitalization with mechanical ventilation support with high use of broad-spectrum antibiotics [2-4]	Lower rates of admission to hospital from long-term care facilities may lead to fewer transmission cycles between long-term care facilities and hospitals [2—4]

PPE, personal protective equipment; HCW, healthcare worker; ICU, intensive care unit.

0195-6701/© 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.





Funding sources None.

References

- [1] Jolivet S, Lolom I, Bailly S, Bouadma L, Lortat-Jacob B, Montravers P, et al. Impact of colonisation pressure on acquisition of extended-spectrum β -lactamase-producing Enterobacteriaceae and meticillin-resistant *Staphylococcus aureus* in two intensive care units: a 19-year retrospective surveillance. J Hosp Infect 2020;105:10–6.
- [2] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
- [3] Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Asian Critical Care Clinical Trials Group. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020;8:506–17.
- [4] Siegel JD, Rhinehart E, Jackson M, Chiarello L. Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings 2006. Am J Infect Control 2007;35(Suppl. 2):S165–93.
- [5] Liu Y, Li J, Feng Y. Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China. Crit Care 2020;24:56.

[6] Kaier K, Mutters NT, Frank U. Bed occupancy rates and hospitalacquired infections – should beds be kept empty? Clin Microbiol Infect 2012;18:941–5.

> D. Donà^{a,*} C. Di Chiara^b M. Sharland^a o, Institute for

^aPaediatric Infectious Diseases Research Group, Institute for Infection & Immunity, St George's, University of London, London, UK

^bDepartment for Woman and Child Health, University of Padua, Padua, Italy

* Corresponding author. Address: Paediatric Infectious Diseases Research Group, Institute for Infection & Immunity, St George's Hospital, 5th Floor, Lanesborough Wing, Blackshaw Road, Tooting, London SW17 0QT, UK. Tel.: +39 3388946412. *E-mail address:* daniele.dona@unipd.it (D. Donà)

Available online 17 May 2020